Tradestie Institutional Equity Comparison Engine · Market Close Nov 20, 2026

KTTA vs ISPC: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

KTTA Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 6–1 Matrix Metrics)

KTTA Overall Winner 6-Pillar Tally: KTTA 2 – 2 ISPC (2 Tie) Matrix Metrics: KTTA 6 – 1 ISPC

As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) is the stronger overall head-to-head candidate over iSpecimen Inc. (ISPC) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KTTA carries a Unified Composite Score of 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin), whereas ISPC carries 41.6/100 (SELL) at $0.46 (N/M Forward P/E, -1455.3% operating margin).

  • Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ISPC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About KTTA vs ISPC
KTTA NASDAQ Head-to-Head Winner
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap $17.7M
TTM Revenue $486,559
Forward P/E N/M
Beta / 30D Vol 0.68β · 185% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 20.0 Fund 40.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -5.1%) with fading momentum, RSI 50
RSI-14: 49.6 · SMA20: $0.48 · SMA50: $0.47
ISPC NASDAQ
iSpecimen Inc. Common Stock
Services-Commercial Physical & Biological Research
$0.46
-13.58% 1D
Market Cap $3.1M
TTM Revenue $603,744
Forward P/E N/M
Beta / 30D Vol -10.07β · 74% Vol
Unified Composite Score
41.6 / 100 SELL
Tech 25.0 Fund 43.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -29.3%), weak momentum, RSI 16
RSI-14: 16.1 · SMA20: $0.73 · SMA50: $0.97

6-Pillar Scorecard Institutional Category Breakdown (KTTA 2 – 2 ISPC)

Columns: Metric · KTTA · ISPC
1. Valuation Multiples ISPC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 36.3x 0.8x
2. Growth & Scale KTTA
Revenue Growth (YoY) +1498.1% +128.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $486,559 $603,744
Market Cap $17.7M $3.1M
3. Profitability & Quality KTTA
Gross Margin -0.5% -42.1%
Operating Margin 0.0% -1455.3%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -88.8% -303.9%
4. Balance Sheet & Cash Flow ISPC
Cash Generation (TTM) -$18M -$8.7M EBITDA
Cash Flow Margin N/A N/A
Net Cash / Leverage $1.31 Book/Sh · -88.8% ROE $2.6M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Diagnostics & Research Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: KTTA (6) vs ISPC (1)
Institutional Metric KTTA ISPC Criterion Row Edge
Market Capitalization
Scale
$17.7M $3.1M Larger Scale KTTA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+1498.1% +128.9% Higher Growth KTTA
Operating Margin (TTM)
Profitability
0.0% -1455.3% Higher Margin KTTA
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-88.8% -303.9% Higher ROE KTTA
52-Week Range Position
Momentum
11% ($0–$2) 5% ($0–$7) Stronger Trend KTTA
Beta / 30D Volatility
Risk Regime
0.68β · 185% Vol -10.07β · 74% Vol Lower Realized Risk ISPC
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 41.6 / 100 (SELL) Higher Composite KTTA
Trailing 12M Revenue (USD)
Operating Scale
$486,559 $603,744 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-0.5% -42.1% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 36.3x EV/Rev N/M PEG · 0.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$18M ($1.31 Book/Sh · -88.8% ROE) -$8.7M EBITDA ($2.6M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon KTTA +52.72 pp
KTTA: +7.52% · ISPC: -45.2%
3M Horizon KTTA +65.73 pp
KTTA: -5.21% · ISPC: -70.94%
6M Horizon KTTA +55.18 pp
KTTA: -31.59% · ISPC: -86.77%
1Y Horizon KTTA +10.59 pp
KTTA: +0.59% · ISPC: -10.0%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period KTTA Revenue ISPC Revenue KTTA Op. Margin ISPC Op. Margin Margin Leader
FY2020 N/A $10M N/A -29.4% ISPC
FY2021 $0M $10M -29925.7% -53.2% ISPC
FY2022 $0M $10M -2587.3% -97.9% ISPC
FY2023 N/A $10M N/A -112.5% ISPC
FY2024 N/A $10M N/A -137.0% ISPC
FY2025 N/A $0M N/A -465.4% ISPC

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
KTTA UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact KTTA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ISPC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ISPC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
KTTA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $17.7M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
ISPC Moat Profile Cyclical / Execution-Driven Positioning
Diagnostics & Research Operator
Competes within the Diagnostics & Research value chain with $3.1M market capitalization and -1455.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ KTTA vs ISPC Key Questions & Quantitative Answers

As of Nov 20, 2026, Pasithea Therapeutics Corp. (KTTA) is the stronger overall head-to-head candidate over iSpecimen Inc. (ISPC) in the Tradestie Institutional Equity Comparison Engine, winning 6–1 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality). KTTA carries a Unified Composite Score of 42.1/100 (HOLD) at $0.48 (N/M Forward P/E, 0.0% operating margin), whereas ISPC carries 41.6/100 (SELL) at $0.46 (N/M Forward P/E, -1455.3% operating margin). Technical & Structure Timing Caution: KTTA is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.6); meanwhile ISPC is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 16.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

KTTA leads the Growth & Scale pillar: KTTA posts +1498.1% YoY revenue growth and +0.0% YoY earnings growth on $486,559 TTM revenue (-0.5% gross margin, 0.0% operating margin), compared with ISPC at +128.9% YoY revenue growth and +0.0% YoY earnings growth on $603,744 TTM revenue (-42.1% gross margin, -1455.3% operating margin). Across the 6-period historical trajectory (FY2020 to FY2025), KTTA cumulative revenue shifted N/A while ISPC shifted +0.0%. In operating R&D and SG&A reinvestment, KTTA deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for ISPC.

ISPC screens cheaper on headline valuation multiples. KTTA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 36.3x EV/Revenue (unreported FCF margin), whereas ISPC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 0.8x EV/Revenue (unreported EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against KTTA (-88.8% ROE) versus ISPC (-303.9% ROE) capital efficiency.

In options market volatility and institutional positioning, KTTA carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.68β · 185% Vol realized risk). By comparison, ISPC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-10.07β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 20, 2026. For educational research only; not investment advice.